Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
Media Centre
>
Video
Overview
Video
Coverage
Video
7-May-2024
Kazia Interview with Professor Sudha Rao from QIMR Berghofer Medical Research Institute
2-Feb-2024
Kazia Interview with Professor Matt Dun from the University of Newcastle, Australia
4-Dec-2023
2023 Kazia Therapeutics AGM
1-Nov-2023
Interview with Kazia CEO Dr John Friend regarding the Company’s intention to delist from the ASX
17-Jan-2023
Kazia Therapeutics CEO talks $4.5 million capital raise
5-Dec-2022
Kazia Therapeutics talks positive pre-clinical data for EVT801
16-Nov-2022
Kazia Therapeutics AGM 2022
8-Aug-2022
Kazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma
30-Jun-2022
Kazia Therapeutics Webinar - Combating Childhood Brain Cancer
8-Jun-2022
Kazia onto next chapter in Phase 2 brain metastases trial
17-May-2022
Interview with Dr Matt Dun for World DIPG Awareness Day
13-May-2022
Edison TV - Part 1 "Meet Kazia’s management team and hear about paxalisib"
13-May-2022
Edison TV - Part 2 "Paxalisib: Beyond glioblastoma and commercial opportunities"
13-May-2022
Edison TV - Part 3 "EVT801, capital markets and upcoming milestones"
2-May-2022
Kazia Therapeutics Ltd wraps up a busy quarter presenting paxalisib data at the AACR annual meeting
31-Jan-2022
Kazia presents at Edison Open House Global Healthcare 2022
12-Nov-2021
Kazia Therapeutics AGM 2021
8-Nov-2021
Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial
4-Nov-2021
Ticker News hears from Dr James Garner about Kazia's EVT-801 phase 1 clinical trial
26-Oct-2021
Edison TV: Kazia Therapeutics – introducing novel asset EVT-801
14-Sep-2021
Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference
7-Sep-2021
CEO and Managing Director, Dr James Garner, presents at ShareCafe 3 September 2021
22-Jul-2021
Tickers News speaks to Kazia Therapeutics CEO James Garner About GBM Awareness Day
5-Jul-2021
CEO James Garner presents at Gold Coast Investment Showcase
20-May-2021
Edison TV: Kazia Therapeutics - overview and update with CEO James Garner
9-Feb-2021
Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference
9-Apr-2020
Kazia CEO, Dr James Garner discusses the recent positive interim data from the phase II trial of paxalisib in glioblastoma, COVID-19 and the company's recent capital raising
26-Jun-2019
Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2019 Gold Coast Investment Showcase
15-Apr-2019
Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the Wholesale Investor Emergence event in Brisbane
11-Jul-2018
Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase
6-Apr-2018
Dr James Garner speaks with CommSec re our GDC-0084 Phase II trial start
29-Mar-2018
NDF Research Senior Analyst Stuart Roberts interviews Kazia Therapeutics CEO Dr James Garner as the GDC-0084 phase II trial launches in the US
30-Nov-2017
CommSec interview re our new name, Kazia Therapeutics and our clinical trial progress
4-Jul-2017
CommSec Executive Series interviews CEO Dr James Garner on benefits of new business model for patients
1-May-2017
Dr James Garner, CEO, speaks to Canary Networks investment forum
31-Oct-2016
Sky News Interview – In-licensing of GDC-0084